BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company announced its 1Q2025 preliminary financial results. The company continues to execute at a high level by posting record 1Q revenue and continued growth in earnings.